Introduction and overview
Section snippets
Conflict of interest statement
PM Mannucci has received speaker fees for participation at educational meetings organised by Bayer, Grifols, Kedrion Biopharma and Novo Nordisk. F Peyvandi has received honoraria for participating as a speaker at educational meetings organised by Bayer, Baxter, CSL Behring and Novo Nordisk; she has received research grant funding from Biotest, Novo Nordisk and Kedrion, and consulting fees from Kedrion, LFB and Novo Nordisk.
Acknowledgements
Sharon Eastwood of PAREXEL, a medical writer supported by funding from Novo Nordisk Health Care AG, provided drafts and editorial assistance to the authors during preparation of this editorial.
References (42)
- et al.
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
J Thromb Haemost
(2014) - et al.
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
J Thromb Haemost
(2006) - et al.
US experience with recombinant factor VIIa (rFVIIa) for surgery in acquired hemophilia (AH): analysis from the Hemostasis and Thrombosis Research Society (HTRS) registry
Blood
(2012) - et al.
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
Blood
(2012) - et al.
Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents
Semin Hematol
(2006) - et al.
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
J Thromb Haemost
(2012) - et al.
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
J Thromb Haemost
(2004) - et al.
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
J Thromb Haemost
(2012) - et al.
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors
J Thromb Haemost
(2013) - et al.
Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
Neuroradiology
(2007)
Recombinant factor VIIa as haemostatic therapy in advanced liver disease
Blood Transfus
(2013)
Summary of Product Characteristics
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors
J Clin Invest
(1983)
NovoSeven Highlights of Prescribing Information
Treatment of hemophilia: a review of current advances and ongoing issues
J Blood Med
(2010)
Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry
Haemophilia
(2013)
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial
Thromb Haemost
(2006)
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors
Thromb Haemost
(1998)
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
Haemophilia
(2005)
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
Haemophilia
(2012)
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
Haemophilia
(2008)
Cited by (0)
Copyright © 2015 Elsevier Ltd. All rights reserved.